Landing Page

**CCM® Therapy Providing Hope When You Need It**

They’re in your capable hands . . . More than 6 million patients with heart failure are primarily managed by cardiologists in the US today, and both the incidence and prevalence are rising rapidly. Until recently, besides optimizing medical therapies, there were few unique alternatives for treating patients with heart failure.

Now breakthrough device therapies have changed everything for a large majority of NYHA Class III patients. As such, it has never been more important to carefully and accurately assess a given patient’s NYHA class. From now on, Don’t Guess Assess.

Accurately discriminating between NYHA Class II and III is now as important as properly assessing EF to prescribe an ICD for prevention of SCD. With the advent of cardiac contractility modulation therapy, “Hope is Here” for you and your patients who previously had no option except to medically manage through progressively worsening symptoms to the point of LVAD or transplant.

CCM® can be provided early on – within a wide EF range between 25% and 45% – to enhance quality of life while improving functional status for Class III patients not indicated for CRT.

If your symptomatic NYHA Class III patient is medically optimized, they may qualify for CCM®

**Eligibility For CCM® Therapy**

* Ejection Fraction 25-45%
* Class III Heart Failure
* Guideline Directed Medical Therapy
* Normal Sinus Rhythm
* Not indicated for Cardiac Resynchronization Therapy

**CCM® Therapy: A Revolutionary Approach to Heart Failure**

“CCM® therapy has given me my life back. I can’t even call it an impact, it’s literally given me my life back.” - Patient

“I’m pretty much back to all my normal duties around the barn. I think that the benefit you get from that gives you such a better outlook on life, and just continues to get better all the time.” - Patient

“Now, I can go to football games and watch my son coach. My three youngest grandchildren, we’re going to go to Disney World and enjoy our time together – which is all I live for.” - Patient

“I’m pretty surprised by my results. I’ve been able to move boulders in my yard, I’ve pushed a golf cart, I’ve planted trees, I’ve dug up bushes. It’s been a good positive result for me.” - Patient

**About CCM® Therapy**

CCM® delivers non-excitatory electrical signals to the right side of the intraventricular septum during the absolute refractory period of the ventricular contraction, and does not trigger a new action potential. CCM® signals are delivered by the system, which is an implantable pulse generator. This device is implanted in a minimally-invasive procedure under local anesthesia, typically in the right pectoral region. CCM® has been evaluated in patients with heart failure with reduced ejection fraction (HFrEF) In contrast to a pacemaker or a defibrillator, the system is designed to modulate the strength of contraction of the heart muscle rather than the rhythm. CCM® therapy is delivered at regular intervals throughout the day.

**Clinical Trials**

Clinical trials have demonstrated statistically significant and clinically meaningful improvements in the FIX-HF-5C randomized trial:

* CCM® subjects improved 11.7 points in the MLWHFQ score compared to the control group
* CCM® subjects improved their NYHA heart failure status by >1 class 81% of the time compared to 42% in the control group
* CCM® subjects walked on average 33.7 meters further than the control group during the 6-minute hall walk test

**Insurance Coverage**

We have pathways to payment with Medicare and commercial payors in multiple care settings – inpatient, outpatient and surgery centers. Additionally, we have a range of resources available for facilities, practitioners and patients related to obtaining access to the system. We have committed ourselves to maximizing availability of Cardiac Contractility Modulation to patients who would benefit from it.

**What Providers are saying about CCM® Smart Therapy**

“I see probably in the neighborhood of 20-25 patients a month who would benefit from CCM® Therapy, specifically.” – Doctor or Nursing Practice

“The FDA granted breakthrough designation to this device and the reason they did that is because this is the first device-based therapy in this population that can reduce symptoms when medications alone are not enough.” – Electrophysiologist

“I’ve been amazed at how virtually every single one of my patients has seen a transformation in their life, having received this therapy.” – Electrophysiologist

“I think if you’re feeling that you have run out of options for the treatment of your heart failure and you haven’t had a conversation with a cardiologist or an electrophysiologist about the role of CCM®, then I think that there are still potential options for you, and you really aren’t at the end of the road.” – Electrophysiologist

“I’ve had patients that were wheelchair bound that were able to walk again.” – Electrophysiologist

**Contact Us**

Fill out the subscribe form to receive information on CCM® Therapy. A representative will reach out to you to provide more information.

**Fields**

* First Name
* Last Name
* Email Address